Ceryvyn Therapeutics Ltd
OPT
Classificação em ações
#31879
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Preço da ação
$0.00846342
Última sincronização: 2026-07-27
Valor de mercado
$11.27M
Variação (1 dia)
0.00%
Variação (1 ano)
-99.75%
País
AU
Negociar Ceryvyn Therapeutics Ltd (OPT)
Categoria
Healthcare
EPS de Ceryvyn Therapeutics Ltd (OPT)
EPS em June 2025 TTM: $-1.84
De acordo com os últimos relatórios financeiros e o preço das ações da Ceryvyn Therapeutics Ltd, o EPS atual da empresa (TTM) é $-1.84. No final de 2024, a empresa teve um EPS de $-22.16, uma diminuição em relação a ao EPS de 2023, que foi de $-3.60.
Histórico de EPS da Ceryvyn Therapeutics Ltd de 2000 até 2026
EPS no final de cada ano
| Ano | EPS | Alterar |
|---|---|---|
| 2026 (TTM) | $-1.84 | -100.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | $-22.16 | 515.56% |
| 2023 | $-3.60 | 32.35% |
| 2022 | $-2.72 | 88.89% |
| 2021 | $-1.44 | 317.39% |
| 2020 | $-0.35 | -31.78% |
| 2019 | $-0.51 | 17.71% |
| 2018 | $-0.43 | 106.64% |
| 2017 | $-0.21 | -6.98% |
| 2016 | $-0.22 | 3.66% |
| 2015 | $-0.22 | -59.90% |
| 2014 | $-0.54 | -17.14% |
| 2013 | $-0.65 | -18.62% |
| 2012 | $-0.80 | -57.76% |
| 2011 | $-1.89 | 132.13% |
| 2010 | $-0.81 | -26.12% |
| 2009 | $-1.10 | 503.62% |
| 2008 | $-0.18 | -113.42% |
| 2007 | $1.36 | -307.90% |
| 2006 | $-0.65 | -130.68% |
| 2005 | $2.13 | 344.53% |
| 2004 | $0.48 | -270.17% |
| 2003 | $-0.28 | -13.83% |
| 2002 | $-0.33 | 328.31% |
| 2001 | $-0.08 | -179.65% |
| 2000 | $0.10 | 0.00% |
EPS de empresas semelhantes ou concorrentes
| Empresa | EPS | Diferença de EPS | País |
|---|---|---|---|
| $17.32 | -1,041.30% |
US
|
|
| $-7.98 | 333.70% |
US
|
|
| $-5.29 | 187.50% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,607.61% |
NL
|
